Inducing neutrophil recruitment in the liver of ICAm-1-deficient mice using polyethyleneimine grafted with Pluronic P123 as an organ-specific carrier for transgenic ICAM-1

Gene Therapy

Volumn 9, Issue 14, 2002, Pages 939-945

  Ochietti, B ^a   Lemieux, P ^b   Kabanov, A V ^c   Vinogradov, S ^c   St Pierre, Y ^a   Alakhov, V ^b  

^a INRS INSTITUT ARMAND FRAPPIER   (Canada)

^b Supratek Pharma Inc   (Canada)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Gene therapy; ICAM 1; Immune response; Liver; Neutrophil invasion; Non viral gene delivery

Indexed keywords

CELL ADHESION MOLECULE; CHEMOKINE; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; NAKED DNA; PLASMID DNA; POLOXAMER; POLYETHYLENEIMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; EFFECTOR CELL; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; LIVER; LYMPHOCYTE HOMING; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE SPECIFICITY; TRANSGENE; TRANSGENIC MOUSE; VASCULAR ENDOTHELIUM;

ANIMALS; CHEMOTAXIS, LEUKOCYTE; GENE EXPRESSION; GENE THERAPY; INJECTIONS, INTRAVENOUS; INTERCELLULAR ADHESION MOLECULE-1; LIVER; LIVER DISEASES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUTROPHILS; PLASMIDS; POLOXALENE; POLYETHYLENEIMINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

ANIMALIA; MURINAE; MUS MUSCULUS;

EID: 0036319690     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301716     Document Type: Article

References (48)

1. Inflammatory and immune responses are impaired in mice deficient in intercellular adhesion molecule 1
2. Leukocytosis and resistance to septic shock in intercellular adhesion molecule 1-deficient mice
3. P-selectin and ICAM-1 mediate endotoxin-induced neutrophil recruitment and injury to the lung and liver
4. Liver metastases are enhanced in homozygous deletionally mutant ICAM-1 or LFA-1 mice
5. Measurement of serum circulating intercellular adhesion molecule-1 and its clinical significance in hepatocellular carcinoma: Preliminary report
6. Circulating intercellular adhesion molecule-1 in chronic liver disease and hepatocellular carcinoma
7. Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma
8. Critical role of leukocyte function-associated antigen-1 in liver accumulation of CD4+NKT cells
9. Cytotoxic activity against tumour cells mediated by intermediate TCR cells in the liver and spleen
10. Antimetastatic effect of NK1+ T cells on experimental haematogenous tumour metastases in the liver and lungs of mice
11. Involvement of liver-associated immunity in hepatic metastasis formation
12. Critical role of leukocyte function-associated antigen-1 in liver accumulation of CD4+NKT cells
13. FMLP- and TNF-stimulated monoclonal Lym-1 antibody-dependent lysis of B lymphoblastoid tumour targets by neutrophils
14. Monoclonal Lym-1 antibody-dependent cytolysis by neutrophils exposed to granulocyte-macrophage colony-stimulating factor: Intervention of FcgammaRII (CD32), CD11b-CD18 integrins and CD66b glycoproteins
15. In vivo induction of functional Fc gammaRI (CD64) on neutrophils and modulation of blood cytokine mRNA levels in cancer patients treated with G-CSF (rMetHuG-CSF)
16. Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12
17. The generation of endostatin is mediated by elastase
18. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9)
19. Microvascular expression of MALA-2 correlates with in vivo lymphocyte trafficking and is preferentially enhanced in tumors by tumor necrosis factor-alpha and interleukin-1 alpha
20. Phase I trial of simultaneous administration of interleukin 2 and interleukin 4 subcutaneously
21. Phase II clinical trial of 13-cis-retinoic acid and interferon-alpha-2a in patients with advanced esophageal carcinoma
22. Daily subcutaneous ultra-low-dose interleukin 2 with daily low-dose interferon-alpha in patients with advanced renal cell carcinoma
23. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models
24. Macrophage inflammatory protein 3alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth
25. Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication
26. Evaluation of polyether-polyethyleneimine graft copolymers as gene transfer agents
27. Novel isoforms of murine intercellular adhesion molecule-1 generated by alternative RNA splicing
28. Inhibition of mixed lymphocyte response by a rat monoclonal antibody to a novel murine lymphocyte activation antigen (MALA-2)
29. Leukocyte-endothelial cell recognition: Evidence of a common molecular mechanism shared by neutrophils, lymphocytes, and other leukocytes
30. Flow cytometric identification of murine neutrophils and monocytes
31. Interactions between red blood cells and a lethal, partly quaternized tertiary polyamine
32. Lipid-mediated enhancement of transfection by a nonviral integrin-targeting vector
33. Immunotargeting of liposomes to activated vascular endothelial cells: A strategy for site-selective delivery in the cardiovascular system
34. Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer
35. In vivo targeted gene transfer into liver cells mediated by a novel galactosyl-D-lysine/D-serine copolymer
36. Receptor-mediated gene transfer to cells of hepatic origin by galactosylated albumin-polylysine complexes
37. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm
38. Suppression of experimental allergic neuritis by an antibody to the intracellular adhesion molecule ICAM-1
39. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1
40. Antisense intercellular adhesion molecule-1 (ICAM-1) oligodeoxyribonucleotide delivered during organ preservation inhibits posttransplant ICAM-1 expression and reduces primary lung isograft failure
41. Optimization of ex vivo pressure mediated delivery of antisense oligodeoxynucleotides to ICAM-1 reduces reperfusion injury in rat cardiac allografts
42. An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice
43. Murine hepatic microvascular adhesion molecule expression is inducible and has a zonal distribution
44. Circulating forms of intercellular adhesion molecule (ICAM)-1 in mice lacking membranous ICAM-1
45. Enhanced expression of ICAM-1 in a murine fibrosarcoma reduces tumor growth rate
46. Herpes simplex virus (HSV)-mediated ICAM-1 gene transfer abrogates tumorigenicity and induces anti-tumor immunity
47. Analysis of T cell stimulation by super-antigen plus major histocompatibility complex class II molecules or by CD3 monoclonal antibody: Costimulation by purified adhesion ligands VCAM-1, ICAM-1, but not ELAM-1
48. Cotransfection of ICAM-1 and HLA-DR reconstitutes human antigen-presenting cell function in mouse L cells